在皮肤黑色素瘤中,DOCK2调节免疫检查点抑制剂的反应和预后,通过多细胞和单细胞T细胞动态的分析
Huicong Wang1, Chao Feng1, Chengjun Lao1
1Department of Dermatology, Shengli Oilfield Central Hospital, 31 Jinan Road, Dongying, 257000, Shandong Province, China.
Discover oncology
|November 19, 2025
概括
细胞动力学2分标 (DOCK2) 是皮肤皮肤黑色素瘤 (SKCM) 的有前途的预后标记物. 更高的DOCK2水平与更好的免疫疗法反应和增加的T细胞透相关,这表明其在精确瘤学中的潜力.
科学领域:
- 在瘤学瘤学.
- 免疫学 免疫学 免疫学
- 遗传学 是一个遗传学.
背景情况:
- 皮肤皮肤黑色素瘤 (SKCM) 是一种侵袭性癌症,发病率和死亡率不断增加.
- 目前的治疗方法,如免疫疗法,表现出不同的疗效和耐药性.
- 需要新的治疗目标来改善SKCM治疗结果.
研究的目的:
- 为了研究细胞动力学2 (DOCK2) 基因在黑色素瘤中的作用.
- 评估DOCK2的预后意义和作为SKCM治疗点的潜力.
主要方法:
- 利用TCGA,GTEx和HPA数据集的综合生物信息学分析.
- 在恶性瘤中评估了DOCK2表达及其在SKCM中的预后价值.
- 对DOCK2相关基因进行了功能丰富分析.
主要成果:
- 在各种癌症中DOCK2表达变化,是SKCM中有利的预后标志物.
- 升高的DOCK2与免疫检查点抑制剂 (ICI) 的改善反应相关.
- DOCK2与免疫通路,白细胞介导免疫和SKCM中T细胞透率增加有关.
结论:
- DOCK2显示出作为黑色素瘤免疫治疗疗效的预后生物标志物的潜力.
- DOCK2值得进一步研究,因为它是SKCM精密免疫治疗的目标.
- 准DOCK2可能会导致SKCM患者改善治疗策略.
相关概念视频
Adaptive Mechanisms in Cancer Cells
6.9K
Cancer cells accumulate genetic changes at an abnormally rapid rate due to the defects in the DNA repair mechanisms. From an evolutionary perspective, such genetic instability is advantageous for cancer development. Mutant cell lines accumulate a series of beneficial mutations that contribute to their progression into cancer.
Some of the advantages that cancer cells have on normal cells include - enhanced ability to divide without terminally differentiating, induce new blood vessel formation,...
Some of the advantages that cancer cells have on normal cells include - enhanced ability to divide without terminally differentiating, induce new blood vessel formation,...
6.9K
Tumor Immunotherapy
1.7K
Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
1.7K
mTOR Signaling and Cancer Progression
4.6K
The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
The mTOR pathway or the...
4.6K


